1.广州中医药大学中药学院,广东 广州 510006
2.热带生物资源教育部重点实验室 / 海南大学药学院,海南 海口 570228
3.广州中医药大学第二附属医院Ⅰ期临床研究室,广东 广州 510120
陈思竹(1999年生),女;研究方向:天然药物活性成分的结构修饰;E-mail:20221110076@stu.gzucm.edu.cn
曹影影(1990年生),女;研究方向:中药药理学;E-mail:caoyingying@gzucm.edu.cn
何细新(1972年生),男;研究方向:天然药物化学;E-mail:mark07@gzucm.edu.cn
网络出版日期:2025-01,
收稿日期:2024-12-22,
录用日期:2025-01-09
移动端阅览
陈思竹, 王雪, 吴银飞, 等.
CHEN SIZHU, WANG XUE, WU YINFEI, et al. The synthesis of
陈思竹, 王雪, 吴银飞, 等.
CHEN SIZHU, WANG XUE, WU YINFEI, et al. The synthesis of
以
α-
倒捻子素为先导化合物,对其C-3及C-6位羟基进行结构修饰,经烷基化、水解反应引入不同碳链长度的羧酸酯、羧酸、酰胺取代基,设计并合成了18个衍生物。采用[
3
H]标记液体闪烁计数法测试了衍生物体外抑制磷酸二酯酶4(PDE4)活性。活性测试结果表明5个衍生物(
2a~6a
)的PDE4抑制活性优于
α
-倒捻子素,其中7碳链长度的羧酸类衍生物
5a
的活性最强(IC
50
319 nmol/L)。
Based on
α
-mangostin as the lead compound, and using the primary methods including alkylation and hydrolysis reactions for modifying C-3 and C-6 positions, eighteen novel derivatives with different chain length of carboxylic acid ester, carboxylic acid, and amide substituents in the C-3, C-6 phenolic hydroxyl group of
α
-mangostin were designed and synthesized. The
in vitro
eval
uation of these compounds' ability to inhibit PDE4 was conducted using the [³H] liquid scintillation counting technique. The experimental results showed that five compound (
2a
-
6a
) had the stronger inhibitory activity on PDE4 than
α
-mangostin. Among them, carboxylic acid derivative of seven carbon chain lengths
5a
exhibited the best potential PDE4 inhibitory activity with the IC
50
values of 319 nmol/L.
α-倒捻子素衍生物磷酸二酯酶4
α-mangostinderivativesphosphodiesterase 4(PDE4)
邓金辉,黄悦,梁津豪,等, 2022. α-倒捻子素衍生物合成及其抑制磷酸二酯酶4活性研究[J].中山大学学报(自然科学版),61(3):53-61.
梁津豪, 2020. α-倒捻子素衍生物的设计、合成及其抑制磷酸二酯酶4活性研究[D].广州: 广州中医药大学.
袁海华, 荀航, 曹先爽,等,2024. 黄酮类化合物抑制β-酮酰基-ACP还原酶的构效关系研究[J]. 林产化学与工业, 44(4): 18-28.
于思, 2018. α-倒捻子素衍生物合成及其抑制磷酸二酯酶 4 活性研究[D]. 广州: 广州中医药大学.
BAGCHI A, ROY A, HALDER A, et al, 2024. The hidden potential of PDE4 inhibitor rolipram: A multifaceted examination of its inhibition of MMP2/9 reveals therapeutic implications[J]. bioRxiv, 16.594542.
BAILLIE G S, TEJEDA G S, KELLY M P, 2019. Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: Inhibition and beyond[J]. Nat Rev Drug Discov, 18(10): 770-796.
DU B, LUO M, REN C, et al, 2023. PDE4 inhibitors for disease therapy: Advances and future perspective[J]. Future Med Chem, 15(13): 1185-1207.
GONG B, VITOLO O V, TRINCHESE F, et al, 2004. Persistent improvement in synaptic and cognitive functions in an alzheimer mouse model after rolipram treatment[J]. J Clin Investig, 114(11): 1624-1634.
HUANG Y Y, DENG J, TIAN Y J, et al, 2021. Mangostanin derivatives as novel and orally active phosphodiesterase 4 inhibitors for the treatment of idiopathic pulmonary fibrosis with improved safety[J]. J Med Chem, 64(18): 13736-13751.
KAWAMATAWONG T, 2021. Phosphodiesterase-4 inhibitors for Non-COPD respiratory diseases[J]. Front Pharmacol, 12: 518345.
KUMAR N, GOLDMINZ A M, KIM N, et al, 2013. Phosphodiesterase 4-targeted treatments for autoimmune diseases[J]. BMC Medicine, 11: 1-8.
LI H, ZUO J, TANG W, 2018. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases[J]. Front Pharmacol, 9: 1048.
LIANG J, HUANG Y Y, ZHOU Q, et al, 2020. Discovery and optimization of alpha-mangostin derivatives as novel PDE4 inhibitors for the treatment of vascular dementia[J]. J Med Chem, 63(6): 3370-3380.
LIU J, ZHANG X, CHEN G, et al, 2023. Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors[J]. Eur J Med Chem, 262: 115893.
MAURICE D H, KE H, AHMAD F, et al, 2014. Advances in targeting cyclic nucleotide phosphodiesterases[J]. Nat Rev Drug Discov, 13(4): 290-314.
MORRIS G M, GOODSELL D S, HALLIDAY R S, et al, 1998. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function[J]. J Comput Chem, 19(14): 1639-1662.
MORRIS G M, HUEY R, LINDSTROM W, et al, 2009. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility[J]. J Comput Chem, 30(16): 2785-2791.
PENG T, QI B, HE J, et al, 2020. Advances in the development of phosphodiesterase-4 Inhibitors[J]. J Med Chem, 63(19): 10594-10617.
PHILLIPS J E, 2020. Inhaled phosphodiesterase 4(PDE4) inhibitors for inflammatory respiratory diseases[J]. Front Pharmacol, 11: 259.
PICCHIANTI-DIAMANTI A, SPINELLI F R, ROSADO M M, et al, 2021. Inhibition of phosphodiesterase-4 in psoriatic arthritis and inflammatory bowel diseases[J]. Int J Mol Sci, 22(5): 2638.
SUHANDI C, WILAR G, NARSA A C, et al, 2024. Updating the pharmacological effects of α-mangostin compound and unraveling its Mechanism of Action: A computational study review[J]. Drug Des Devel Ther,2024,18: 4723-4748.
WACHTEL H, SCHNEIDER H H, ROLIPRAM, 1986. A novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors[J]. Neuropharmacology, 25(10): 1119-1126.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构